MedTrace Logo

The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient

NCT01424345 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 4

Last updated 2026-03-20

No results posted yet for this study

Summary

The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.

Conditions

  • Kidney Transplant Immunosuppression

Interventions

DRUG

adjustment of immunosuppressant dosages

adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results

DRUG

adjustment of the dosages of immunosuppressants

adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab

Sponsors & Collaborators

  • CAMC Health System

    lead OTHER

Principal Investigators

  • S Jeff Chueh, MD PhD · CAMC Health System, Charleston, WV

  • Bashir Sankari, MD · CAMC Health System, Charleston, Wv

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01424345 on ClinicalTrials.gov